Antibodies

29 Sep 2019 ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
29 Sep 2019 Bristol-Myers Squibb Announces Final Results from CheckMate -227 Part 1 Demonstrating Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) vs. Chemotherapy in Advanced Non-Small Cell Lung Cancer
29 Sep 2019 Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress
29 Sep 2019 ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor
29 Sep 2019 Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer
29 Sep 2019 FDA Approves Genentech’s Rituxan (rituximab) in Children With Two Rare Blood Vessel Disorders
29 Sep 2019 Northern Biologics Reports Phase I Data Update for MSC-1, an Anti-LIF Antibody, at ESMO
27 Sep 2019 Genentech’s Tecentriq (Atezolizumab) Improves Overall Survival as a First-line Monotherapy in Certain People With Advanced Non-small Cell Lung Cancer
27 Sep 2019 European Commission Approves Trogarzo
27 Sep 2019 Kymab Outlines Positive New Findings for its KY1044 Anti-ICOS Program at the CICON 2019 Annual Meeting
27 Sep 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
27 Sep 2019 Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
27 Sep 2019 Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress
25 Sep 2019 Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
25 Sep 2019 Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment
25 Sep 2019 UCB presents UCB0107 anti-Tau immunotherapy Phase I study results at World Movement Disorders Conference
24 Sep 2019 Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease who have Undergone C
24 Sep 2019 Immutep to Receive £4M Milestone Payment From GSK
24 Sep 2019 Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis
23 Sep 2019 Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO
22 Sep 2019 CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
20 Sep 2019 2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors
20 Sep 2019 CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
20 Sep 2019 CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
19 Sep 2019 Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top